Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Lutetium Li 177 dotatate was linked with partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors, per real-world data.

Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs

Benjamin Besse, MD, PhD, shares AE management strategies with amivantamab/lazertinib in EGFR-positive NSCLC following CHRYSALIS-2 results.

Safety Management With Amivantamab Plus Lazertinib in NSCLC

Tepotinib was associated with frequent but manageable adverse events in MET exon 14–positive NSCLC, with peripheral edema most common.

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Ghayas C. Issa, MD, MS, discusses key adverse events of menin inhibitors in NPM1-mutated and KMT2Ar AML.

Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

From All Angles

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Events

Subscribe

Partners

Michelle Kirschner, RN, MSN, ACNP, APRN-BC, is a nurse practitioner and director of program development at the Cancer Survivorship and Supportive Care Professionals Network.

Bridget Hoyt is the assistant editor for Oncology Nursing News. She earned her BA in communication studies at Rider University with a minor in public relations. She can be reached at 

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, discusses how precision supportive care tailors interventions to patient needs.

Precision Supportive Care Centers Patient Preference in Oncology

Articles

Benjamin Besse, MD, PhD, is the director of Clinical research at Gustave Roussy.

Abigail T. Ramontal, MHP, MSN, APRN-FP-C, is an advanced practice nurse at Sylvester Comprehensive Cancer Center at the University of Miami in Miami, Florida.

Read an advanced practice nurse's tips for treating patients with endometrial cancer with durvalumab.

Rx Road Map: Durvalumab for Endometrial Cancer

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News – Clinical Insights for Cancer Care Nurses

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

The combination of apalutamide to carotuximab showed early signs of tolerability in patients with metastatic castration-resistant prostate cancer.

Preliminary Findings Show Tolerability of Carotuximab Combo in mCRPC

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Gedatolisib Combos Show Early Activity in mCRPC, Metastatic Breast Cancer

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.

Oncology Drugs Approved by the FDA in June

Patients with metastatic CRPC who maintained PSMA expression had a median OS of 14.5 months with 177Lu-PSMA-617 retreatment.

Retreatment With 177Lu-PSMA-617 May Benefit mCRPC With Sustained Expression

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.

Ga-68 Kit Approved for Pre-Taxane RLT Selection in mCRPC

Barry Goy, MD, discusses decrease in sexual function and increase in quality of life that may occur with the addition of SADT to EBRT for patients with intermediate-risk prostate cancer.

Barry Goy, MD, discusses benefits and risks of EBRT plus SADT.

Though some factors like sexual function may be negatively affected, the addition of short-term neoadjuvant androgen deprivation therapy (SADT) may increase quality of life (QOL) for patients with intermediate-risk prostate cancer (IRPC), according to an oncologist.

Barry Goy, MD, spoke with Oncology Nursing News about possible adverse effects of SADT at the 

2025 American Society of Clinical Oncology Genitourinary Cancers Symposium

, where his research on external beam radiation therapy (EBRT) in conjunction with SADT was presented.

Goy explained some of the benefits and risks of EBRT and SADT, including alleviating some of the mental burden of a decreased QOL with IRPC. While it may not always be cost-efficient for patients with intermediate or lower risk, he said it may be beneficial for those living with IRPC. Goy is a radiation oncologist at Kaiser Permanente Los Angeles Medical Center.

You always ask the patients in regards to their sexual function. Some patients are still very active, although, for most patients, though, when they have recurrence, it tends to be years later from their initial treatment, so things have changed, maybe, and it may not be as important to them.

So, you know, putting patients on salvage [androgen deprivation therapy] does have some side effects, although by and large, usually it's fairly tolerable.

And the other consideration is a mental consideration, psychologic consideration, because some patients are extremely nervous about their PSA recurrence. So some patients we wind up treating just because mentally, their quality of life goes down…even though it may not kill them.

I don't know if that's the most cost-effective treatment for patients with recurrent prostate cancer, but…those are some of the considerations that I take into account.

This transcript has been edited for clarity and conciseness.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Benefits, Risks With EBRT Plus SADT in Intermediate-Risk Prostate Cancer

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Michael Lai, ARNP, on the mechanism of action of PARP inhibitors for prostate cancer.

In the treatment of prostate cancer, PARP inhibitors can lead to double-strand DNA breaks, thus resulting in cancer death, and expert said.

With prostate cancer cells, PARP inhibitors can selectively target pathogenic DNA damage repair mutations such as 

 to potentially improve the control of a patient’s cancer, said Michael Lai, ARNP, Fred Hutchinson Cancer Center Teaching Associate in the Division of Hematology and Oncology at the University of Washington School of Medicine. Some PARP inhibitors include olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula).

At the recent 8th Annual School of Nursing Oncology, Lai presented on the optimized use of PARP inhibitors in the treatment of patients with prostate cancer. He also spoke with Oncology Nursing News to understand the mechanism of action of PARP inhibitors and how they can further benefit patients.

The PARP inhibitor class of drugs work by inhibiting the PARP protein, which is an enzyme involved in single-strand DNA repair. By inhibiting PARP, this can lead eventually to double-strand DNA breaks.

Now, typically, a normal cell without any issues in its DNA repair will rely on the powerful homologous recombination repair process to address double-strand DNA breaks and perform then the needed DNA damage repair to survive. But if you have a cell with a key mutation in homologous recombination repair, particularly 

, then without this machinery in play, using a PARP inhibitor at that time, thereby also shutting down this avenue for single-strand DNA repair, can essentially open up a lethal vulnerability and result in cancer cell death.

So specifically in prostate cancer cells, we can selectively target those with known pathogenic DNA damage repair mutations like 

, and hopefully better control patients’ cancer.

This transcript has been edited for clarity

Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer

In the genitourinary cancer space, there have been a lot of updates to follow in the past 5 years. At the 

, a nurse practitioner at Seattle Cancer Care Alliance, about why he thinks there have been so many updates recently.

I think that it's sort of a coalescence of a number of different things, timing, maybe a little bit of luck, and there's just a lot more interest in bladder cancer these days. It's a deadly disease when it's metastatic, and we're trying to find options that go beyond the first and second line that can really prove to have some survival benefit. For prostate cancer, it's such a common ubiquitous disease amongst men, and so, it just makes sense to continue the research in this realm and provide all the options that we can. 

The genitourinary cancer space has seen a lot of updates in the past 5-10 years, but where are they all coming from so suddenly? Oncology Nursing News spoke with Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance, about how the genitourinary cancer space has been able to have so many updates recently.

Where New Updates in Genitourinary Cancer Continue to Come From

Prostate cancer tumors tend to be "cold," meaning that they may have difficulty responding to immunotherapy treatment. But combining agents may help improve their responsiveness, explained 

, a nurse practitioner at Seattle Cancer Care Alliance. 

So in prostate cancer, we're looking at, for example, immunotherapy and utilizing this in that context. For immunotherapy, what we're doing right now is, as opposed to doing a single-agent model, using dual agents, because prostate cancer can tend to be a relatively "cold" tumor. So if you use something like docetaxel first or in conjunction with immunotherapies like pembrolizumab (Keytruda) or standard-of-care agents such as abiraterone (Zytiga), the idea is: can we warm up the tumor so that the prostate cancer is more susceptible to immunotherapy agents such as pembrolizumab or others.

Can combining agents turn "cold" prostate cancer tumors "hot"? 

Prostate Cancer

Latest News

Latest Conference Coverage